Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study

B cells take their time: sequential IgG class switching over the course of an immune response?

(2014) Menno C van Zelm   IMMUNOLOGY AND CELL BIOLOGY

Timing of an Adolescent Booster after Single Primary Meningococcal Serogroup C Conjugate Immunization at Young Age; An Intervention Study among Dutch Teenagers

(2014) Susanne P. Stoof et al.   PLoS One

Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children

(2014) Shousun C. Szu et al.   VACCINE

Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials

(2013) Zulfiqar A Bhutta et al.   LANCET INFECTIOUS DISEASES

A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned

(2013) Shousun C. Szu et al.   VACCINE

Guinea pigs in human form: clinical trials in unethical settings

(2012) Subrata Chattopadhyay   LANCET

Population-Based Incidence of Typhoid Fever in an Urban Informal Settlement and a Rural Area in Kenya: Implications for Typhoid Vaccine Use in Africa

(2012) Robert F. Breiman et al.   PLoS One

Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: A cluster randomized trial in Karachi, Pakistan

(2012) M. Imran Khan et al.   VACCINE

Epidemiology, clinical presentation, and patterns of drug resistance of Salmonella Typhi in Karachi, Pakistan

(2012) M. Imran Khan et al.   Journal of Infection in Developing Countries

Preparation and evaluation of immunogenic conjugates ofSalmonella entericaserovar Typhi O-specific polysaccharides with diphtheria toxoid

(2012) Aamir Ali et al.   Human Vaccines & Immunotherapeutics

The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant Vaccines

(2011) Vu Dinh Thiem et al.   Clinical and Vaccine Immunology

Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines

(2011) Jan Poolman et al.   Expert Review of Vaccines

Human IgG isotypes and activating Fcγ receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells

(2011) Yun S. Goh et al.   IMMUNOLOGY

Avidity of Serogroup A Meningococcal IgG Antibodies after Immunization with Different Doses of a Tetravalent A/C/Y/W135 Polysaccharide Vaccine

(2011) G. K. Bårnes et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines

(2010) Gregory A. Poland   CLINICAL INFECTIOUS DISEASES

A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India

(2009) Dipika Sur et al.   NEW ENGLAND JOURNAL OF MEDICINE

Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever

(2009) James E. Froeschle et al.   VACCINE

a study of typhoid fever in five Asian countries: disease burden and implications for controls

(2008) R Leon Ochiai   BULLETIN OF THE WORLD HEALTH ORGANIZATION